Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESENT study of pemafibrate versus fenofibrate in NAFLD with hypertriglyceridemia
jRCTs031200280Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pemafibrate and fenofibrate in metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia (3 arms), sponsored by Kowa Company, Ltd. Started Feb 2021; status: completed.
02
Drugs
pemafibratefenofibrate
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)hypertriglyceridemia
Beyond the preview
Go deeper on jRCTs031200280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200280.